Although acute dexmedetomidine administration may phosphorylate tau protein through α2-AR, it was recently found that dexmedetomidine and clonidine, the agonists of α2-AR, can inhibit sevoflurane-induced tau protein phosphorylation and cognitive impairment by activating α2-AR (Sun et al., 2021). The gene discussed is MAPT; the disease is Cognitive impairment.